This review analyzing different retrospective and prospective CLL cohorts highlights the need to detect TP53 mutations with highly sensitive NGS technology in a routine setting due to the clonal expansion of minor clones after CIT. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.